Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory Scleritis and Orbital Inflammation
NCT00415506Phase 2Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2007
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in scleritis and orbital inflammation (IOIS) (2 arms), sponsored by Oregon Health & Science University. Primary endpoints: Reduction of Medications at 24 weeks and Improved Control of Inflammation at 24 weeks. Started Jan 2007; status: completed.
02
Drugs
rituximab
03
Conditions
scleritisorbital inflammation (IOIS)
Beyond the preview
Go deeper on NCT00415506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415506.